| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825457 | Clinical Therapeutics | 2013 | 9 Pages |
Abstract
Both treatment options were well tolerated and equally reduced BP. The results support the conclusion that group A (new fixed-dose combination of ramipril/HCTZ) was noninferior to group B (reference medication in Brazil). ISRCTN Register: ISRCTN05051235.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Wille PhD, Marco Antônio Mota BSc, Antônio Carlos PhD, Rui PhD, Osvaldo PhD, João Carlos BSc, Fernando PhD,